Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study
暂无分享,去创建一个
A. Grzeszczuk | M. L. Jakobsen | J. Minton | M. Jakobsen | B. Gazzard | A. Mocroft | A. d’Arminio Monforte | J. Lundgren | A. Sullivan | D. Raben | Y. Yazdanpanah | J. Rockstroh | N. Clumeck | J. Minton | E. Ong | A. Vassilenko | V. M. Mitsura | N. Clumeck | V. Hadziosmanovic | U. B. Dragsted | A. Palfreeman | A. Grzeszczuk | A. Cabié | D. Raben | A. Mocroft | M. Rayment | Z. M. Sthoeger | A. Palfreeman | S. Morris | G. Kutsyna | C. Necsoi | V. P. Estrada | V. Svedhem Johansson | J. Begovac | E. L. C. Ong | A. Cabié | F. Ajana | B. M. Celesia | F. Maltez | M. Kitchen | L. Comi | J. Gatell | B. Gazzard | A. d’Arminio Monforte | J. Rockstroh | Y. Yazdanpanah | K. Champenois | A. Sullivan | J. D. Lundgren | B. Celesia | J. Gatell | V. Estrada | V. Johansson | F. Ajana | C. Necsoi | L. Comí | K. Champenois | M. Kitchen | S. Morris | A. Vassilenko | M. Rayment | V. Hadžiosmanović | G. Kutsyna | V. Mitsura | J. Begovac | Z. Sthoeger | F. Maltez
[1] R. Walensky,et al. Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness , 2010, PloS one.
[2] Y. Yazdanpanah,et al. Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study , 2013, BMC Infectious Diseases.
[3] A. Mocroft,et al. Late presentation of HIV infection: a consensus definition , 2011, HIV medicine.
[4] G. Pedersen,et al. Late presenters, repeated testing, and missed opportunities in a Danish nationwide HIV cohort , 2012, Scandinavian journal of infectious diseases.
[5] A. Mocroft,et al. Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral Therapy Across Europe , 2006, Journal of acquired immune deficiency syndromes.
[6] M. Leszczyszyn‐Pynka,et al. [Late AIDS diagnosis in patients hospitalized in Clinic of Infectious Diseases and Hepatology PAM in years 2003-2007]. , 2009, Przeglad epidemiologiczny.
[7] Anne M Johnson,et al. Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE) , 2013, PLoS medicine.
[8] Andrew N. Phillips,et al. Projected life expectancy of people with HIV according to timing of diagnosis , 2012, AIDS.
[9] W. Henrich,et al. Testing for HIV during pregnancy: 5 years after changing German pregnancy guidelines , 2013, Archives of Gynecology and Obstetrics.
[10] J. Arnold,et al. Antenatal screening and prevalence of infection: surveillance in London, 2000-2007. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[11] Milton C Weinstein,et al. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. , 2005, The New England journal of medicine.
[12] J. Casabona,et al. HIV testing : increasing uptake and effectiveness in the European Union Evidence synthesis for Guidance on HIV testing , 2010 .
[13] Milton C Weinstein,et al. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. , 2002, Archives of internal medicine.
[14] E. O. D. Op de Coul,et al. Antenatal screening for HIV, hepatitis B and syphilis in the Netherlands is effective , 2011, BMC infectious diseases.
[15] A. Nardone,et al. HIV Testing in Non-Traditional Settings – The HINTS Study: A Multi-Centre Observational Study of Feasibility and Acceptability , 2012, PloS one.
[16] Douglas K Owens,et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. , 2005, The New England journal of medicine.
[17] Stefan Esser,et al. Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study) , 2013, PloS one.